ArticleAntimicrobial agents and chemotherapy2021
Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Pooled it
- Review
- Management of extensively drug-resistantASM case reports · 2025Article
- The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-ResistantMicroorganisms · 2025Review
- Sulbactam for carbapenem-resistantJAC-antimicrobial resistance · 2025Review
- Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Successful Treatment of OXA-23Infection and drug resistance · 2025Article
- Retrospective analysis of the impact of pathogen spectrum and antibiotic resistance on the treatment efficacy of respiratory tract infections from 2012 to 2022.American journal of translational research · 2025Article
- Guava Leaf Extract Exhibits Antimicrobial Activity in Extensively Drug-Resistant (XDR)Molecules (Basel, Switzerland) · 2024Article
- Antibiotic Treatment of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Clinical Outcomes for Patients With Monomicrobial vs PolymicrobialOpen forum infectious diseases · 2024Article
- Treatment of infections caused by carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Review
- Cefiderocol and Sulbactam-Durlobactam against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- In Vivo Emergence of Pandrug-ResistantOpen forum infectious diseases · 2023Article
- Acinetobacter baumannii: A multidrug-resistant pathogen, has emerged in Saudi Arabia.Saudi medical journal · 2023Review
- Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.Annals of intensive care · 2023Review
- Salvage therapy with sulbactam/durlobactam against cefiderocol-resistantJAC-antimicrobial resistance · 2023Article
- What was old is new again: Phenotypic screening of a unique fungal library yields pyridoxatin, a promising lead against extensively resistantPhytochemistry letters · 2023Article
- Exploring Synergistic Combinations in Extended and Pan-Drug Resistant (XDR and PDR) Whole Genome SequencedMicroorganisms · 2023Article
- Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extremely drug-resistant (XDR) Acinetobacter baumannii causes challenging nosocomial infections. We report the case of a patient with XDR A. baumannii pneumonia and septic shock successfully treated with cefiderocol and a novel antibiotic obtained via expanded access protocol. With focused research and drug development efforts, the poor outcomes associated with these infections may be mitigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.